design (Sidhu, Landoni, Aliabadi, & Lees, 2010a,b) . Pharmacokinetic (PK) and pharmacodynamic (PD) integration models are ideal methods to establish rational drug dosage regimens (Jacobs, 2001 ) and have been widely used for dose regimen design and prevention of bacterial resistance (Toutain & Lees, 2004) .
For PK/PD integration, several models have been used (in vitro, ex vivo and in vivo models) (Giraudel, Toutain, & Lees, 2005) .
Compared with in vitro and ex vivo models, in vivo models are the preferred approach because of the dynamic interaction of the host, drugs and pathogens (Craig, 1993) . The tissue cage model is an in vivo model that has been widely used in veterinary field for several animal models, such as sheep (Sidhu et al., 2010b) , goats (Sidhu et al., 2010a) , rabbits (Cui et al., 2006; Xiong et al., 2016) , calves (Cao et al., 2015; Potter, Illambas, Pelligand, Rycroft, & Lees, 2013) and pigs (Gu et al., 2015; Zhang et al., 2014) .
In the present study, a standard Chinese strain of Pasteurella multocida was exposed to different doses of cefquinome in piglet tissue cages (TCs). The PK/PD parameters and antibacterial effect were then calculated. This study aimed to evaluate the correlations between the PK/PD indices and the antibacterial effect of cefquinome against P. multocida. Furthermore, the obtained results could provide a framework to design cefquinome-dosing regimens for the treatment of respiratory diseases-related P. multocida infection.
| MATERIAL S AND ME THODS

| Antimicrobials and chemicals
Cefquinome sulphate injections (25 mg/ml, Cobactan, the Batch Number A621B01) were supplied by Merck & Co. Inc. (Boxmeer, the Netherland). A cefquinome sulphate standard with a purity of 80.92% was provided by the China Institute of Veterinary Drugs Control (Beijing, China). Pentobarbital sodium was purchased from Jian Yang Biotechnology Co., Ltd (Guangzhou, China). Procaine hydrochloride was bought from Xin Zheng Co., Ltd (Zhengzhou, China).
Tryptic Soy Broth (TSB) and Tryptic Soy Agar (TSA) were purchased from Guangdong Huankai Microbial Sci. & Tech. Co., Ltd (Guangzhou, China). Neonatal bovine serum and defibrinated sheep blood were bought from Guangzhou Ruite Biotechnology Ltd (Guangzhou, China). Compound aminopyrine injections were purchased from Shandong Zhengmu Biological Pharmaceutical Co., Ltd (Linyi, China). 
| Bacterial strain and susceptibility testing
| Piglet tissue cage infection model and dosage regimen
Sixteen healthy, castrated, crossbred piglets (Duroc × Landrace × Yorkshire), weighing 20-30 kg, were purchased from the Guangzhou Fine Breed Swine Farm. They were housed separately and fed antibiotic-free fodder twice a day, and water was provided ad libitum. All piglets were acclimatized for 7 days and remained healthy during the experiment.
The specification of tissue cages (TCs) and the surgical procedure were the same as those described by Zhang et al. (2014) . During surgery, the piglets were under deep general anaesthesia induced by pentobarbital sodium and local infiltration anaesthesia induced by the injection of procaine hydrochloride. Two sterile TCs were implanted subcutaneously on each side of the animal's neck, approximately equidistant from the jugular vein and spinal cord. After surgery, the animals were allowed to recover for approximately 4 weeks to induce wound healing and tissue cage fluid production.
Piglets were administered with penicillin intramuscularly and tetracycline ointment was applied to the skin covering the TCs twice Sterile TCs were used for infection experiment. The TCs were inoculated with 1 ml of P. multocida saline suspension (1.5 × 10 8 colony forming units (CFU)/ml). After 48 hr of incubation, the TCs containing bacterial counts of approximately 10 7 CFU/ml were applied for the following experiment. Sixteen animals were randomly divided into six treatment groups (two piglets, four TCs/group) and one untreated control (infected but not treatment) group (four piglets, eight TCs). Each treatment group was administered cefquinome intramuscularly once a day for 3 days at 0.2, 0.4, 0.8, 1, 2, and 4 mg/ kg, respectively. The untreated control group simultaneously received sterile physiological saline (1 ml) by the same method.
| Bacteriological examination of tissue cage fluid and pharmacokinetics of cefquinome
An approximately 0.5 ml sample of TCF was collected from the TC before and at 24 hr after each drug administration during the entire treatment process, and at 24, 48, and 72 hr after the last drug administration. The samples were 10-fold diluted in sterile physiological saline, and 20 μl was plated onto a TSA plate for overnight incubation at 37°C to count the bacterial population. The theoretical lower limit of detection was 50 CFU/ml. The bacterial kill curves (Gu et al., 2015) were constructed using the bacterial population obtained at 0, 24, 48, 72, 96, and 120 hr for each drug dosage. The antibacterial effect of cefquinome against P. multocida was defined as the reduction in the amount of bacteria over 24 hr after every administration of cefquinome.
For the pharmacokinetic analysis, TCF samples were collected from the TCs at 1, 3, 6, 9, 12, and 24 hr after each dose, and at 48 and 72 hr after the last treatment. After clarification by centrifugation at 3,000 g for 10 min, the supernatant was stored at −20°C until further analysis. The concentration of cefquinome was detected using the method described by Zhang et al. (2014) . The standard curve of cefquinome was quantified using a range of concentrations between 5 and 500 ng ⁄ml, and the limitation of quantification was 5 ng/ml.
| Pharmacokinetics/pharmacodynamics integration and modelling
For PK/PD integration, the surrogate indices, such as %T > MIC where E is the antibacterial effect, determined as the log 10 (CFU/ml) reduction in bacterial counts in the TCF samples; E max is the change in bacterial count in the control sample (in the absence of cefquinome) during the dosing interval; and E 0 is the maximum antibacterial effect during the dosing interval. EC 50 is the value of PK/PD parameters that produced 50% of the maximum antibacterial effect.
C e is the value of the PK/PD parameters (%T > MIC, C max (TCF) /MIC, and AUC 24 hr (TCF) /MIC). N is the Hill coefficient that describes the gradient of the PK/PD indices versus the antibacterial effect curve.
| RE SULTS
| Pharmacokinetics of cefquinome in tissue cage fluid
The concentration-time curves of cefquinome following multiple dosing are shown in Figure 1 , and the mean values of AUC 24 hr (TCF) and C max (TCF) are shown in Table 1 . The pharmacokinetics of cefquinome was analysed using the noncompartmental method.
The mean values of AUC 24 hr (TCF) ranged from 0.313 ± 0.125 to 5.329 ± 1.884 μg hr/ml. The values of C max (TCF) ranged from 0.026 ± 0.004 to 0.457 ± 0.180 μg/ml. In addition, the mean values of %T > MIC ranged from 18.538 ± 0.954 to 98.088 ± 5.868% (Table 1) .
| Antibacterial activity
The MICs of cefquinome against P. multocida were 0.016 μg/ml in TSB and 0.016 μg/ml in TCF.
The time-kill curves are shown in Figure 2 . The antibacterial activity of cefquinome against P. multocida (strain C44-15) was calculated as the reduction in bacterial counts (log 10 CFU/ml) over 24 hr after every administration and the values were shown in Table 2 
| Pharmacokinetic-pharmacodynamic modelling and analysis
An inhibitory sigmoid E max model was used to analyse the relationships between the antibacterial effect and PK/PD indices (AUC 24 hr (TCF) /MIC, C max (TCF) /MIC, and %T > MIC) and the results are shown in Table 3 , and the values of %T > MIC to achieve a 1/3-log, 1/2-log, and 1-log reduction in the P. multocida count were 14.23%, 34.45%, and 73.44%, respectively, during the 24-hr period of cefquinome treatment.
| D ISCUSS I ON
Pasteurella multocida is a natural inhabitant of the mucosal surfaces of vertebrates. It is an opportunistic pathogen and common inhabitant of the upper respiratory tract of many animal species.
It is also a causative agent of numerous economically important diseases worldwide, including fowl cholera in poultry (Blackall, Pahoff, Marks, Fegan, & Morrow, 1995) , atrophic rhinitis in swine (Kalorey et al., 2008) , and haemorrhagic septicaemia in cattle and buffaloes (Aalbaek et al., 1999) . As a pathogen commonly observed in secondary infections, it frequently plays a major role in the progression of disease to a severe form of pleuropneumonia in swine and ruminants . In addition, the antibacterial resistance was severe in humans and animals because of nonrationally designed dose regimens. Resistance can occur in two ways. One is the selection of resistance resulting from the overgrowth of a pre-existing subpopulation with a lower level of susceptibility after low drug dosages (Schentag et al., 1998 Note. The bacterial count reduction after every drug administration (at 24 hr dosing intervals) is expressed as a positive value. The last line is the total bacterial count reduction after three administrations of cefquinome. The mean initial bacterial concentration of the six dosages before treatment was 7.45 CFU/ml.
TA B L E 2
The tissue cage fluid bacterial count reduction (log 10 CFU/ml) for each drug administration at six dosage regimens after three administrations of cefquinome Dosage (mg/kg) AUC 24 hr (TCF) (μg hr/ml) C max (TCF) (μg/ml) %T > MIC Note. AUC 24 hr (TCF) : area under the concentration-time curve in the TCF from 0 to 24 hr after every administration; C max (TCF) : the maximum concentration in TCF over 24 hr after each administration. The AUC 24 hr (TCF) and C max (TCF) were the mean values of multiple-dose administration (three times).
The values shown are means ± SD.
TA B L E 1
The tissue cage fluid pharmacokinetic parameters of cefquinome other reason for the emergence of resistance is that bacteria are exposed to suboptimal drug concentrations (Burgess, 1999) . In our study, recovery of bacteria was observed in the low dose regimens (0.2 and 0.4 mg/kg), which easily induced the production of resistant bacteria. A bactericidal effect was achieved at dosages of 1, 2, and 4 mg/kg. Therefore, rational antibiotic therapy requires dosage regimens to be optimized, not only to guarantee clinical efficacy, but also to minimize the selection and spread of resistant pathogens (Toutain et al., 2002) .
Cefquinome is a cephalosporin antibiotic that shows a high correlation between antibacterial activity and %T > MIC (Zonca et al., 2011) . To investigate this relationship in vivo, several animal models have been used; for example, a rabbit TC model infected with
Staphylococcus aureus (Xiong et al., 2016) , a piglet TC model infected with Escherichia coli (Gu et al., 2015) , and the neutropenic mouse thigh model infected with Staphylococcus aureus (Wang, Shan, Ding, Liang, & Zeng, 2014) . In the present study, we used a piglet TC infection model to assess the pharmacodynamics of cefquinome against P. multocida. The results confirmed that the %T > MIC value correlated markedly with the efficacy of cefquinome against P. multocida.
In the design rational dosage regimens, the magnitudes of PK/PD parameters play an important role. Several studies used the estimated magnitude of %T > MIC to predict the efficacy of cefquinome. A previous study assessed cefquinome efficacy against E. coli (Gu et al., 2015) and showed that during a 12-hr treatment period, continuous bacterial count reductions of 1/6-log, 1/3-log, and 1/2-log were achieved when the %T > MIC reached 3.97, 17.08, and 52.68%, respectively. Another report (Xiao et al., 2015) studied the effect of cefquinome against Haemophilus parasuis and 3-log and 4-log reductions of the bacterial count were achieved when the %T > MIC value reached 61 and 71%, respectively. Shan and Wang (2017) explored the interaction of cefquinome with extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumonia and the magnitudes to achieve net bacterial stasis, 1-log 10 kill and 2-log 10 kill over 24 hr were 20.07%, 29.57%, and 55.12%, respectively. In our experiment, the values of %T > MIC that produced a 1/3-log, 1/2-log, and 1-log reduction in the P. multocida count during 24 hours of cefquinome treatment were 14.23, 34.45, and 73.44%, respectively.
In the present study, the TC model was successfully established to evaluate the interaction between cefquinome and P. multocida in vivo; however, there are still some limitations of our study. The subcutaneous compartment tissue condition was different for deeper airways and the equilibrium of tissue-to-plasma is different to the lung-to-plasma because of the lung-blood barrier. In addition, only the free drug produces the antibacterial activity; therefore, the free drug in the lung interstitial fluid is highly relevant to the antibacterial effect. Therefore, a further study to explore the PD and PK integration in lung epithelial ling fluid is necessary.
In conclusion, in this experiment, piglets received multiple dosages, which accommodated clinical treatment. The interaction between the cefquinome concentration and P. multocida in the tissue cage real reflected the relationship of PK/PD integration.
Cefquinome exhibited a time-dependent killing efficacy against P. multocida and %T > MIC was the best PK/PD parameter to predict the antibacterial effect. After administrated of cefquinome once daily for 3 days, a 3-log reduction in P. multocida was achieved when the %T > MIC reached 73.44%. Furthermore, the results derived from this study provide meaningful guidance for the design of reasonable clinical treatment regimens for P. multocida infection in pigs.
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